|Day's Range||29.50 - 29.50|
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced today that it will provide updates on its partnered epilepsy programs at the American Epilepsy Society (AES) Annual Meeting held in Baltimore, MD.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
SAN DIEGO and BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Xenon Pharmaceuticals Inc. (XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosciences gains an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, demonstrating that treatment with once-daily 40 mg or 80 mg of INGREZZA reduced involuntary movements in adults who had moderate or severe tardive dyskinesia (TD) and clinical diagnoses of schizophrenia, schizoaffective disorder or a mood disorder.
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy ...
Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington's ...
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Conference Call and Webcast Scheduled for Monday, November 4 SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial ...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Pooled Data Analyses from Long-Term Studies Show that the 40 mg Once-Daily Dose of INGREZZA is Effective in Reducing Abnormal Movements in Adults with Tardive Dyskinesia - Data Analysis Indicates that ...
SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disorder. A data analysis will also be presented on the long-term effects of INGREZZA in patients who demonstrated improvement in TD symptoms as early as two weeks.
SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs ...